Cultipharm and Zambon Announce Strategic Agreement for the Development of Advanced Nutraceutical Product Lines
Cultipharm, an Italian company specialized in the research and production of botanicals obtained through Controlled Environment Agriculture (CEA), announces a strategic agreement with Zambon, a multinational chemical-pharmaceutical company founded on the history and values of a an italian family committed to improving patients’ lives and health. This partnership aims at the joint development and global commercialization of new advanced nutraceutical product lines of botanical origin.
Therefore, the partnership is focused on the development of innovative botanical products supported by scientific validation and intended for future advanced nutraceutical formulations by Zambon for the management of diseases and conditions across its therapeutic areas, with the objective of improving patients’ quality of life.
The collaboration will integrate Cultipharm’s expertise in controlled botanical cultivation and phytochemical characterization with Zambon’s international experience in clinical development, regulatory affairs, and commercialization of healthcare solutions.
Cultipharm SuperActives are botanical ingredients designed to deliver optimized, distinctive, and reproducible phytochemical profiles. Controlled environment cultivation, combined with in-depth research and precise identification of the optimal harvesting/maturation time (balsamic time), enables modulation of the production of target active compounds. Addressing the pharmaceutical, nutraceutical, and cosmetic sectors, they represent an advanced formulation solution that combines standardization, customization, and enhancement of the plant’s full spectrum of active compounds.
Particularly, Cultipharm’s CEA model not only ensures high-quality standards of active pharmaceutical ingredients (APIs) but also significantly reduces water and land consumption, eliminates the use of pesticides and contaminants, and lowers the environmental footprint of the entire supply chain.
“We are very pleased with our strategic partnership with Zambon, with whom we aim to lay the foundations for a new generation of nutraceutical products combining nature and science, focusing on safe and effective formulations supported by robust scientific evidence,” said Alessandro Algeri, Chief Executive Officer of Cultipharm. “This agreement enables us to continue contributing to the evolution of phytotherapy by offering sustainable, short-supply-chain- and Made-in-Italy-products.”
“We are excited to collaborate with Cultipharm to bring patients effective, safe, and sustainable advanced nutraceutical solutions,” said Massimo Grandi, Chief Core Therapies Officer of Zambon. “For Zambon, sustainability means implementing concrete actions to shape the future by adopting initiatives that have a tangible impact on human and environmental health.”